Chronic altitude illness

Jul 25, 2021 by in RESPIRATORY Comments Off on Chronic altitude illness

24 Chronic altitude illness Introduction Chronic mountain sickness Historical Epidemiology of CMS Clinical aspects of CMS Hemodynamics Prevention Treatment Pathophysiology of CMS with normal lungs Excessive erythrocytosis with lung disease…

read more

Genetics and genomics of exposure to high altitude

Jul 25, 2021 by in RESPIRATORY Comments Off on Genetics and genomics of exposure to high altitude

6 Genetics and genomics of exposure to high altitude Introduction History Variation at the molecular level Omics analysis Candidate genes Hypoxia-inducible factors Description of hypoxia-inducible factors HIF responses to hypoxia…

read more

Low-Density Lipoprotein Cholesterol Treatment Rates in High Risk Patients: More Disappointment Despite Ever More Refined Evidence-Based Guidelines.

Jul 16, 2021 by in CARDIOLOGY Comments Off on Low-Density Lipoprotein Cholesterol Treatment Rates in High Risk Patients: More Disappointment Despite Ever More Refined Evidence-Based Guidelines.

American physicians are now treating dyslipidemia according to a fifth iteration of national guidelines for the use of lipid-lowering therapies . These guidelines are developed with considerable care and deliberation…

read more

Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States

Jul 16, 2021 by in CARDIOLOGY Comments Off on Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States

Abstract Objective We assessed national- and state-level geographic variations among patients with a history of ≥1 major atherosclerotic cardiovascular disease (ASCVD) event in: (1) the proportion of patients with retrospectively…

read more

Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: A collaborative clinical practice statement

Jul 16, 2021 by in CARDIOLOGY Comments Off on Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: A collaborative clinical practice statement

Highlights • HFrEF is a debilitating disease with substantial morbidity, mortality, and costs. • SGLT2i reduce adverse cardiovascular (including HF) and renal events. • SGLT2i have ushered in a new…

read more
Get Clinical Tree app for offline access